Glenmark Pharmaceuticals reported a substantial increase in its financial performance for Q4 FY26, with consolidated net profit skyrocketing to ₹301.41 crore, a remarkable growth from ₹4.65 crore in Q4 FY25. Revenue from operations also saw a 16.8% year-on-year increase, reaching ₹3,760.28 crore. The profit before tax (PBT) experienced a significant rise to ₹387.77 crore, compared to ₹7.97 crore in the same quarter last year. The company's performance was bolstered by a 29.4% increase in revenue from North America, totaling ₹924.8 crore, and a 21.4% rise in Europe, reaching ₹890.7 crore. For the fiscal year ending March 31, 2026, Glenmark's net profit grew by 30.06% to ₹1,361.85 crore. Chairman Glenn Saldanha highlighted the year as a pivotal one for the company, emphasizing the successful launch of key generic respiratory products and the strategic partnership with AbbVie. Additionally, the board approved the transfer of nebulizer brands to Glenmark Healthcare for ₹223 crore, expected to be completed by June 30, 2026.